TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of distal subungual onychomycosis affecting at least one great toenail~* KOH positive at screening~* Willingness not to use any other products including nail polish applied to the toenails during the study~* Women of childbearing potential who are currently sexually active must agree to use contraception for the entire study period~Exclusion Criteria:~* Concurrent or recent use of certain topical or systemic medications without a sufficient washout period~* History of any significant chronic fungal disease other than onychomycosis~* Significant confounding conditions as assessed by study doctor~* Participated in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AN2690 Topical Solution, 5% (Type: EXPERIMENTAL): AN2690 Topical Solution, 5%
- Solution Vehicle (Type: PLACEBO_COMPARATOR): Solution Vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin Attenuates Inflammation in Human Cerebral Aneurysms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age 18-80 years.~2. Incidental (non-ruptured) IA ≥5 mm.~3. Treating neurosurgeon and patient agree on observation period of 3 months before proceeding with treatment either endovascularly or by microsurgical clipping.~4. Positive MRI signal change corresponding of ferumoxytol uptake is observed.~5. No history of aspirin intake or NSAIDs for 4 weeks prior to enrolment.~6. No current history of statin use.~Exclusion Criteria:~1. Patients with treated IAs (by coil embolization or surgical clipping) will be excluded.~2. Patients presenting with ruptured intracranial IAs will also be excluded from the study, to avoid interfering with timely treatment of ruptured IAs.~3. Children~4. pregnant women~5. persons with history of allergy or hypersensitivity to iron or dextran or iron-polysaccharide preparations~6. patients requiring monitored anesthesia or intravenous (IV) sedation for MR imaging~7. patients with contraindication to MRI~8. patients with renal insufficiency, hepatic insufficiency or iron overload, 9. patients receiving combination antiretroviral therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- aspirin (Type: EXPERIMENTAL): aspirin 81 mg po every day
- no aspirin (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Rheumatoid arthritis as defined by the 1987 ACR classification~* Severe active seropositive disease~* Inadequate response or intolerance to other DMARDs and anti-TNFs~* Treatment with Methotrexate~Exclusion Criteria:~* Patients with systemic manifestations of rheumatoid arthritis~* Female patients nursing~* Women of childbearing potential unless using birth control~* Active infection~* Known immunodeficiency syndrome~* Positive Hepatitis B surface antigen or antibodies to Hepatitis C~* History of cancer~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GP2013 (Type: EXPERIMENTAL): None
- MabThera (Type: ACTIVE_COMPARATOR): None
- Rituxan (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Wharton Jelly in Erectile Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male patients ranging from 25 to 70 years.~2. History of chronic erectile dysfunction for at least six months.~3. Baseline international index of erectile function (IIEF) score of \< 26.~4. Not interested or able to use phosphodiesterase type 5 inhibitor (PD5i) drug therapy and willing to forgo theses treatments for the first 6 month period following study treatment.~5. Body Mass Index between 20-30.~6. Willing to provide written informed consent, complete questionnaire, and to be available for all baseline treatment and follow up examinations required by protocol.~Exclusion Criteria:~1. Current urinary tract or bladder infection.~2. Clinical/Laboratory evidence of transmissible diseases.~3. Clinically evident penile anatomical deformities(e.g., Peyronie's disease) or history of priapism.~4. Skin irritation, infection, wound, sore or disruption in the immediate areas of skin entry for penile injection.~5. Current or previous malignancy.~6. Use of any non study treatment for erectile function within 4 weeks of study treatment.~7. Lack of willingness to continue through 6 months after study treatment.~8. Any previous penile implant or penile vascular surgery.~9. Uncontrolled hypertension or hypotension(systolic blood pressure \> 170 or \< 90 mm Hg, and diastolic blood pressure \> 100 or \< 50 mm Hg).~10. Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening.~11. Bleeding or clotting disorder, use of anticoagulant therapy.~12. Lab values for complete blood count (CBC), prothrombin time (PT)/ partial thromboplastin time (PTT)/ international normalized ratio (INR), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine falling outside the normal lab values.~13. Systemic autoimmune disorder.~14. Significant active systemic or localized infection.~15. Receiving immunosuppressant medications.~16. Post-radical prostatectomy.

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Dose I (Type: EXPERIMENTAL): Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Detection of PitNET Tissue During TSS Using Bevacizumab-800CW

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with an established diagnosis of PitNET with a Knosp grade of 3 or 4 who are scheduled to undergo TSS.~* WHO performance status 0-2~* Signed written informed consent~Exclusion Criteria:~* Medical or psychiatric conditions that compromise the patient's ability to give informed consent~* Pregnant or lactating women. Documentation of a negative pregnancy test must be available for woman of childbearing potential. Woman of childbearing potential are pre- menopausal women with intact reproductive organs and women less than two years after menopause~* History of infusion reactions to bevacizumab or other monoclonal antibody therapies.~* Inadequately controlled hypertension with or without current antihypertensive medication~* Within 6 months prior to inclusion: myocardial infarction, TIA, CVA, pulmonary embolism, uncontrolled chronic hepatic failure, unstable angina pectoris

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NIR endoscopic TSS with 4.5 mg bevacizumab-800CW (Type: EXPERIMENTAL): IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
- NIR endoscopic TSS with 10 mg bevacizumab-800CW (Type: EXPERIMENTAL): IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.
- NIR endoscopic TSS with 25 mg bevacizumab-800CW (Type: EXPERIMENTAL): IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to 3 patients with a pituitary neuroendocrine tumor (PitNET) with a Knosp grade of 3 or 4. The optimal dose will be expanded to include 6 patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A stroke specialist-determined ischemic stroke or TIA within the past year (including ocular strokes/TIA such as amaurosis fugax).~* Presence of systemic hypertension (average systolic blood pressure over two visits - i.e., SPC visit and study screening visit- exceeding 140 mmHg) OR fasting LDL cholesterol exceeding 2.0 mmol/L OR total: HDL cholesterol ratio exceeding 4.0 at SPC visit.~Exclusion Criteria:~* Neurological event considered to be due to intracranial hemorrhage (e.g., ICH, SAH), or trauma induced, or related to structural heart disease such as ASD/VSD or endocarditis.~* Foreshortened life-expectancy (e.g., active malignancy), hypertensive crisis (clinic systolic BP \> 200 mm Hg), or severe comorbidities.~* Institutionalized in a long-term care facility.~* Cognitive impairment (defined as a score of \> 5 on the Short Portable Mental Status questionnaire).~* Already on maximal therapy for risk factors (on 3 antihypertensive drugs at maximal dose if hypertension is inclusion criterion or on maximal dose statin if hyperlipidemia is inclusion criterion).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensive pharmacist case management (Type: EXPERIMENTAL): None
- Usual care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta -agonist therapy by inhalation.~* Pre-bronchodilator FEV1 \>75% of predicted at screening.~* Non-smoker~* Demonstration of a positive reaction to at least one allergen from a battery of allergens (including house dust mite, grass pollen and cat hair on skin prick testing at screening, or within 12 months of study start.~* Have Asthmatic response~* Able and willing to give written informed consent to take part in the study.~* Available to complete all study measurements.~Exclusion criteria:~* History of cardiovascular disease~* Clinically significant abnormalities in safety laboratory analysis at screening including any subject who has greater than trace urine protein levels following urinalysis at screening.~* History of hayfever~* The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.~* The subject has tested positive for HIV antibodies.~* The subject has positive drugs of abuse test.~* Subjects weighing less than 50kg are to be excluded from participating in the study.~* The subject has participated in a study with a new molecular entity during the previous 3 months.~* History of being unable to tolerate or complete methacholine, and/or allergen challenge tests.~* There is a risk of non-compliance with study medication or study procedures.~* History of blood donation (450 mL) within 2 months of starting the clinical study.~* The subject regularly drinks more than 28 units of alcohol in a week if male, or 21 units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of wine, half a pint (250 ml) of beer or one measure (24 ml) of spirits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Main Inclusion Criteria:~* Written Informed Consent has been obtained~* OAB (symptoms of urgency) according to International Children's Continence Society (ICCS) criteria~* Daytime incontinence with at least 4 or more episodes of incontinence confirmed by 7 day participant diary~Main Exclusion Criteria:~* Daily voiding frequency less than 5~* Extraordinary daytime urinary frequency according to the International Children's Continence Society (ICCS) definition~* Uroflow indicative of pathology other than OAB~* Maximum voided volume (morning volume excluded) \> expected bladder capacity for age \[(age +1) x 30\] in ml or a maximum voided volume (morning volume excluded) above 390 ml~* Post Void Residual (PVR) \> 20 ml~* Monosymptomatic enuresis~* Polyuria defined as \> 75 ml/kg/b.w./24 hours~* Dysfunctional voiding~* Congenital anomalies affecting lower urinary tract function~* Current constipation~* Current Urinary Tract Infection (UTI)~* Catheterization within 2 weeks prior to screening

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Children (Type: PLACEBO_COMPARATOR): Children aged 5 to 11 years received matching placebo suspension once a day for 12 weeks.
- Solifenacin Succinate Suspension Children (Type: EXPERIMENTAL): Children aged 5 to 11 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
- Placebo Adolescents (Type: PLACEBO_COMPARATOR): Adolescents aged 12 to 17 years received matching placebo suspension once a day for 12 weeks.
- Solifenacin Succinate Suspension Adolescents (Type: PLACEBO_COMPARATOR): Adolescents aged 12 to 17 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a DSMIV diagnosis of bipolar I disorder, current episode manic or mixed.~Exclusion Criteria:~* Patients with unstable medical conditions or clinically significant laboratory abnormalities or patients who are rapid cyclers (ie. have had 4 or more (including current) mood episodes in the past 12 months); have any other psychiatric disorder other than bipolar I disorder as a primary diagnosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Asenapine
- Arm 2 (Type: ACTIVE_COMPARATOR): Olanzapine
- Arm 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age~2. Has end stage renal disease (ESRD) and is to receive a kidney transplant from a living donor (LD) to whom he/she has either:~   1. A positive crossmatch requiring pretransplant desensitization (defined as a positive T-cell FCXM of greater than or equal to 300 but less than 450 prior to desensitization, or as a positive B-cell FCXM of \> 300 but \< 450 prior to desensitization with demonstrable Class II donor specific alloantibody (DSA) on solid-phase assays). Subsequent to desensitization, patient must have, at the time of transplant, a T-cell and B-cell FCXM less than 300; or~  2. A positive crossmatch not requiring desensitization (defined as FCXM between 200 and 299)~3. Willing to comply with the protocol~4. Females of child-bearing potential must have a negative pregnancy test (serum β-HCG) and sexually active females must agree to use a reliable and medically approved method of contraception~5. Willing and able to give written informed consent~6. Vaccinated against Neisseria meningitides (quadrivalent vaccine), Pneumococcus or H. influenzae at least two weeks prior to beginning desensitization~Exclusion Criteria:~1. Unstable cardiovascular condition~2. Previous splenectomy~3. Active bacterial or other infection which is clinically significant in the opinion of the investigator~4. Known or suspected hereditary complement deficiency~5. Participation in any other investigational drug study or was exposed to an investigational drug or device within 30 days of randomization~6. Pregnant, breast-feeding, or intending to conceive during the course of the study, including the two month follow-up period after drug discontinuation~7. Known hypersensitivity to the treatment drug or any of its excipients~8. History of illicit drug use or alcohol abuse within the previous year~9. History of meningococcal disease~10. Medical condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, pose an added risk for the patient, or confound the assessment of the patient (e.g. severe cardiovascular or pulmonary disease)~11. Previously been enrolled in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Patients received eculizumab intravenously according to details provided in the intervention description.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fresolimumab In Systemic Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet ACR criteria for diffuse systemic sclerosis~* \< 24 months since onset of first SSc manifestation other than Raynaud's phenomenon~* Modified Rodnan Skin Score ≥ 15~* Male or female adult ( ≥ 18 years of age)~* Able and willing to give written informed consent and comply with study protocol~Exclusion Criteria:~* Moderate or severe pulmonary disease w/ FVC \< 80% or DLCO \< 70% or ground glass and fibrosis \> 20% of lung fields by HRCT~* Treatment with investigational drug within 4 weeks of screening~* Ongoing use of high dose steroids (\> 10mg/day) or unstable steroid dose in past 4 weeks~* Treatment with immunosuppressive, cytotoxic, or antifibrotic drug within 4 weeks of screening~* Positive for HIV, HBV, and/or HCV~* Known active infection (bacterial, viral, fungal, mycobacterial, or other); not including fungal infection of nail beds or any major infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening~* Patients w/ history of malignancy or premalignant lesion~* History of keratoacanthoma or squamous cell carcinoma~* Moderate to severe hepatic impairment~* SSc renal crisis within 6 months or creatinine \> 2.0~* Lack of IV access for medication administration~* Moderate or severe cardiac disease with significant arrhythmia, heart failure, or unstable angina~* Anemia (Hb \< 8.5 gm/dL)~* Thrombocytopenia or blood clotting disorder~* Patients with organ transplant (including allogeneic bone marrow transplant)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fresolimumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete